Cancer biology grants

For early-career independent investigators (lab established 3–8 years prior to Dec 31, 2026; appointment start 2018–2023) at non-profit academic/research institutions worldwide. Supports high-impact, high-risk cancer research distinct from the applicant's current portfolio. Single PI only; no co-investigators. Applicants must have multi-year independent funding active in 2027. All materials must be submitted in English.

For early-career clinicians with a medical degree and previous experience in cancer research or treatment. Fellowship funds research experience abroad. Requires two support letters and proof of sponsorship from an eligible host organisation. Applications must be submitted online via the GAP portal.

Open to independent scientists at Swiss research institutions. Covers basic, clinical, epidemiological, psychosocial and health services cancer research. Only industry-independent projects with clear cancer relevance are eligible. Maximum one ongoing project per main applicant. Submissions must be made online via the GAP portal.

Three non-targeted major grants of €600k each for biological, clinical, epidemiological and psychosocial cancer research conducted in Finland. Grants will not be awarded to researchers funded by the tobacco industry. Results announced December 2026.

Annual autumn call for major grants, research grants, and doctoral dissertation grants in cancer research. Awarded by the Board of the Cancer Foundation Finland. Includes dissertation (doctoral) grants making it relevant for early-career researchers as well. Finnish institution affiliation expected; largest private cancer research funder in Finland.

Research grants for 1–3 years for scientific cancer research in Finland; longer periods prioritised. Also available to newly established research groups whose leader has completed a successful postdoctoral period. No grants to tobacco-industry-funded researchers.

Funding for projects that have completed a qualification process and are ready to take the next step toward verification and realisation of the solution. Cancer innovation focus. Applications via SøknadsWeb.

Supports recruitment of international leaders in oncology to French research institutions. Aimed at attracting high-profile international researchers to France in the field of cancer research.

For postdoctoral researchers with <5 years mentored research experience at award activation, working at the intersection of cancer immunology and computational biology/data science. Must be conducted at a non-profit institution (US or abroad); no citizenship restrictions. Sponsor must hold assistant professor or higher rank. Proposals must be hypothesis-driven in basic or translational cancer immunology.

Cancer research stipend (NOK 200,000) for medical doctors during PhD work or continuing research after PhD. Priority given to cancer in children and young people. May be used for international stays or equipment. Full call text at onkologiskforum.org.

Supports postdoctoral researchers in immunology and cancer immunology at non-profit institutions worldwide (no citizenship restrictions). Applicants must hold a doctoral degree by award activation and have <5 years of mentored research experience (M.D.s exclude residency years). Research must be hypothesis-driven and mechanistic, relevant to the immune system's role in cancer. Only 1 fellow per sponsor per round.

Supports outstanding early-career postdoctoral scientists seeking dual expertise in immunology and data science at the intersection of cancer immunology and bioinformatics/computational methods.

Stipend of NOK 200,000 for physicians during PhD work or continuing research after PhD. Priority given to cancer in children and young people. May be used for international stays or equipment. Norwegian applicants.

Funds fundamental (Basic Research phase 1) and Credentialing (phase 2) cancer research, including biological mechanisms of cancer onset/progression and psychosocial impacts. Proposal types: Research Project, Consortium, and Unique High-Risk. Submitted via KWF GMS; participating institutes must register ≥6 weeks before closing. YIG proposals must use the separate 2026/YIG call.

Cancer research stipend prioritising research on cancer in children and young people; also supports other cancer research. Open to physicians during PhD work or as a supplement to continued research after PhD. May be used for international stays or equipment.

Supports group leaders to develop their research programme and build reputation as world-leaders in cancer research. Eligibility criteria changed: no longer accepting new outline applications from clinicians following the May 2026 committee review.

Supports clinician scientists who have gained a higher research degree and some postdoctoral experience, ready to develop their own research niche. Restricted to clinician scientists.

Supports new group leaders who do not have a salaried independent position to establish their independent research group in cancer research.

Supports clinician scientists to transition to research independence and leadership in cancer research. Restricted to clinician scientists; host organisation must contribute towards the fellow's salary.

Supports new group leaders who have a salaried independent position to establish their independent research group. Eligibility changed: no longer accepting new outline applications from clinicians following May 2026 committee review.

Open to scientists, clinicians or healthcare workers based at UK universities, medical schools, hospitals or research institutions with extensive postdoctoral experience and an independent research group. Applicant must be fully funded by host institution for the award duration. Covers primary prevention and population research with cancer relevance, including epidemiology, translational prevention, clinical trials, and behavioural interventions.

Horizon Europe RIA under the EU Cancer Mission supporting development of validated microbiome tools for early cancer prediction before disease onset, including AI risk modelling, longitudinal cohort studies, and comparison with liquid biopsy tests. Proposals must address multiple cancer types where possible and collaborate with large cohorts/registries. Lump sum grant; one grant expected.

Horizon Europe RIA under the EU Cancer Mission call HORIZON-MISS-2026-02. One indicative grant of approximately €15M. Full topic description available in the Work Programme. Consortia must include eligible entities from at least 3 EU member states or associated countries.

Horizon Europe Innovation Action under the EU Cancer Mission call HORIZON-MISS-2026-02. One indicative grant of approximately €7M. Full topic description available in the Work Programme. Consortia must include eligible entities from at least 3 EU member states or associated countries.

Horizon Europe Coordination and Support Action under the EU Cancer Mission call HORIZON-MISS-2026-02. One indicative grant of approximately €5M. Full topic description available in the Work Programme. Consortia must include eligible entities from at least 3 EU member states or associated countries.

Horizon Europe RIA (lump sum) for academic investigator-initiated pragmatic clinical trials on immunotherapeutic interventions for refractory cancer patients. Proposals must include a clinical studies annex, disaggregate data by sex/gender/age, and engage patients in endpoint definition. Applicants must include diverse stakeholders and plan to join the EU Cancer Mission 'Diagnosis and Treatment' cluster. ~3 grants expected.

Horizon Europe RIA under the Cancer Mission. Requires development of multiscale AI-integrated Virtual Human Twins for cancer onset, progression and personalised treatment. Proposals must include clinical study annex if clinical studies are envisaged. Interdisciplinary consortia including healthcare professionals, patient representatives, AI experts and SMEs expected. Open science principles mandatory; data must be shared via UNCAN.eu and Advanced VHT Platform.

Postdoctoral fellowship programme for early-career cancer researchers based in France. Supports young researchers (Jeunes chercheurs) in oncology. Proposals likely in French.

International mobility prize in oncology, co-funded by Fondation ARC and the Société Française du Cancer (SFC). Supports scientific mobility actions. Proposals likely in French.

Supports novel pilot studies and high-risk ideas in cancer early detection and diagnosis. Applicants must be scientists, clinicians or healthcare workers based at a UK university, medical school, hospital or research institution. Open to all career stages and disciplines; no prior cancer research experience required. May fund one investigator's salary. Spotlight call on reducing inequalities in cancer early detection also active.

Prix & récompenses (Awards) in oncology research. Category is prizes/awards — included as it may carry a funded research component. Open call with deadline 21 September 2026.

Add-on to ongoing or recently completed KWF-funded projects (incl. KWF-PPP, TTW Technology for Oncology, KWF-NWO early detection). Innovation must be at TRL ≥3. Supports translational pathway definition, limited development/validation, and regulatory/implementation preparation. Applicants must collaborate with their institution's TTO. Applications submitted during the project or up to 1 year after end date.

Health~Holland PPP programme (KWF, NRG PALLAS, FAST, Oncode Institute) funding development of lead-212 production technology and enabling technologies for radiopharmaceutical cancer therapies. Proposals must include a private party (not in financial difficulty); TKI-LSH Budget Form and Consortium Agreement are mandatory. Projects embedded in Lead4Life governance structure and national TRT network.

Joint scheme with the Pathological Society for pathology trainees (e.g. histopathology, neuropathology) who are members of the Pathological Society of Great Britain and Ireland. Must be a medical trainee in a pathology specialism. Held at a UK university or research institute. Applicants must not have registered for or completed a PhD/MD.

Short-term funding for clinicians and other health professionals to get involved in research projects early in their career. Restricted to clinicians and health professionals; early-career focus.

Supports exploratory drug discovery to validate and de-risk targets for novel single-agent anti-cancer therapeutics. Open to academic researchers worldwide with their own lab or independent research. Projects run collaboratively with Cancer Research Horizons' Therapeutic Innovation team. Not suitable for basic biological research, combination studies, or drug repurposing.

Open to academic researchers worldwide with an independent lab. Focused on cancer target identification or validation of novel cancer targets using novel model systems/analytical methods. Projects run collaboratively with Cancer Research Horizons. Not suitable for fundamental biology, gene-silencing-only approaches in commercial cell lines, or clinical-trial-enabling studies.

Open to academic researchers worldwide with an independent lab. Focused on hit identification, druggability assessment (e.g. fragment screening), or early therapeutic project development using antibody-based or small molecule approaches for adult cancers. Projects run collaboratively with Cancer Research Horizons. US institutions may claim up to 10% indirect costs.

Annual call for cancer research projects with Nordic collaboration. Norwegian Cancer Society contributes annually to this Nordic Cancer Union initiative. Applications via NCU's own portal. Nordic collaboration required.

Knæk Cancer-funded prevention research lab call. Proposals likely in Danish. Full eligibility details available on the funder's website.

Supports innovative, practice-close research projects on cancer prevention and health promotion with potential population-level impact in Denmark. Both a Danish practice partner and a researcher from a recognised institution must be involved. Applicants may hold only one active Knæk Cancer project grant at a time. Results must target publication in a peer-reviewed journal. Proposals must fall within the Danish Cancer Society's prevention policy.

For mid-career researchers at UK universities, medical schools, hospitals or research institutions, salaried via Higher Education Funding Council, NHS or equivalent (salary not fundable from award). Supports cancer biology programmes from molecular to whole-body scale; excludes clinical trials, sole drug discovery, early detection/prevention, and pure technology development. Closed scheme — pre-application contact required.

For established researchers at UK universities, medical schools, hospitals or research institutions pursuing ambitious cancer biology programmes. Applicants must hold a post fully funded by a national Higher Education Funding Council, NHS or equivalent; salary cannot be funded by the award. Closed scheme — contact discovery@cancer.org.uk at least one month before deadline. Excludes clinical trials, drug discovery-only, and early detection/prevention work.

Annual call for cancer research projects with Nordic collaboration. Total pool of €950,000. Applications submitted via NCU's own portal. Questions to ncu@kreftforeningen.no.

Annual call for cancer research projects with Nordic collaboration, funded by Nordic Cancer Union with Norwegian Cancer Society contributions. Total budget €950,000. Information and application portal on NCU's website. Questions to ncu@kreftforeningen.no.

Annual call for cancer research projects with Nordic collaboration. Total budget €950,000. Applications submitted via NCU's own portal. Nordic cross-country collaboration is required.

For new independent group leaders (scientists; clinicians no longer eligible from May 2026) based at a UK university, medical school, hospital or research institution with a fully-funded salary. Applicant must be sole PI. Covers cancer-relevant basic, preclinical, imaging, radiotherapy, EPS, population, and early detection research. Equipment costs capped at £25k; relocation up to £1k.

For established scientist group leaders at UK universities, medical schools, hospitals or research institutes. Applicants must hold a PhD or MD with extensive post-doctoral experience. Clinicians are no longer eligible from May 2026. Host institution must contribute 50% of salary. Sole PI only; full-time commitment expected (min 0.5 FTE for part-time). Covers basic, preclinical, imaging, radiotherapy, EPS, population and early detection cancer research.

For clinician scientists transitioning to research independence in cancer. Applicants must hold GMC registration, a higher degree (MD/PhD), CCT/consultant status, and be based at a UK university, medical school, hospital or research institute. Sole PI only; no fully-funded salary or prior substantial multi-year independent fellowship permitted. Fellows must remain clinically active (20–40% time).

For clinician scientists (MD/PhD) with GMC registration, a national training number, and some postdoctoral experience, hosted at a UK university, medical school, hospital or research institute. Applicants must remain clinically active during the fellowship. Covers cancer-relevant basic, preclinical, imaging, radiotherapy, EPS, population, and early detection research. Full-time basis; part-time possible with approval.

For scientists establishing an independent research group; must be based at a UK university, medical school, hospital or research institute. Applicant must not already hold a fully-funded salaried position or prior substantial multi-year PI fellowship. Sole lead applicant (PI) only; covers cancer-relevant basic, preclinical, imaging, radiotherapy, EPS, population, and early detection research.

For early-career oncology researchers within 5 years of PhD (extensions possible for clinical training or parental leave). Project leader must hold a PhD and be employed ≥0.5 FTE throughout. Covers all research phases from basic to implementation. Applicants must be affiliated with a KWF-registered institute (registration required ≥6 weeks before deadline). Proposals must be submitted exclusively to this call.

Open cancer research call covering Creation of Modality, Preclinical, Clinical, or Implementation research phases. Proposals must include a development plan with steps, stakeholders, feasibility, and risks. Projects falling within scope of specific thematic calls (biomarker validation/implementation, PIPELINE, INTER-LOCAL, pancreatic screening) are excluded. Dutch summary and patient participation section required; PACO review weighted 30%.

Scholar stipends and international stays (udlandsophold) for cancer researchers. Early-career focused. A further round is expected in May 2027. Proposals likely in Danish.

International technical mobility grant (MOBITECH) co-funded by Fondation ARC and the Société Française du Cancer (SFC). Supports technical/scientific international mobility in cancer research. Proposals likely in French.

Funds nationwide implementation of clinically validated oncology biomarkers (TRL 7–9) in the Netherlands. Requires a multidisciplinary consortium of ≥4 parties, an HTA specialist in the team, a KWF-approved steering committee, and structural embedding of the patient perspective. PhD candidates are strongly discouraged. Public/private collaborations encouraged if co-funding is in place.

Clinical validation of known oncology biomarkers (TRL 5/6) for use in daily clinical practice. Requires multidisciplinary consortium of ≥4 parties, mandatory (early) HTA component, patient involvement, and robust statistical expertise. AI-component projects must engage AI4Health consortium. Discovery-phase (TRL 1–4) and side-effect biomarkers are out of scope.

Funds fundamental (basic and credentialing) cancer research covering biological mechanisms of cancer onset/progression and psychosocial impacts. Proposals must be submitted via KWF GMS; participating institutes not yet registered must request access at least 6 weeks before closing. Call 2027-1 is the final project-based Exploration call; from 2028 KWF transitions to Research Group Funding.

Funds fundamental (Basic Research phase 1) and credentialing (phase 2) cancer research, covering biological mechanisms of cancer onset/progression and psychosocial impacts. Applicants must submit via KWF GMS; unregistered institutes must register ≥6 weeks before closing. This is KWF's final project-based Exploration Call; from 2028 KWF transitions to Research Group Funding.

Supports early-stage, pre-development concepts with potential to transform cancer immunotherapy. Targets bold, innovative technology ideas at the pre-development stage in cancer immunotherapy.

Supports early-stage, pre-development technological innovations in cancer immunotherapy (computational, profiling, visualization, culture systems, novel therapeutics). Applicants must hold a tenure-track position at a not-for-profit research institution. Co-PIs encouraged. Does not fund clinical trials or continuation of existing technologies. Proposals must be submitted in English.

Supports innovative investigations at the intersection of laboratory discovery and clinical application in cancer immunology, accelerating translation of immunological discoveries into cancer therapies. Requires integration of clinical and laboratory components.

Supports pioneering immunotherapy clinical trials designed and led by academic researchers. Requires a clinical trial focus; applicants must be academic investigators leading immunotherapy trials.

Open to tenure-track assistant professors or higher at non-profit medical schools and research centers worldwide (US or abroad); no citizenship restrictions. Funds translational cancer immunology research bridging lab discovery and clinical application. For-profit institutions are ineligible. A chordoma-focused sub-track is co-funded with the Chordoma Foundation.

Funds investigator-initiated phase I/II or phase II immunotherapy clinical trials led by academic PIs. Open to researchers at medical schools or research centers in the US or abroad; no citizenship restrictions; for-profit institutions ineligible. Emphasis on novel immunotherapy, mechanistic insights, and biomarker discovery. Up to 10% indirect costs provided in addition to award. Co-funding available for chordoma-focused proposals (with Chordoma Foundation).

UK-based investigators at universities, medical schools, hospitals, UKCRC registered CTUs or research institutions. Investigator-led clinical trials and associated translational/experimental medicine research in cancer. All applications must have a UKCRC registered CTU coordinating the trial/study. Industry-sponsored trials ineligible. Proposals must be submitted in English via Flexi-Grant.

Funds academic-led clinical trials (Phase I–III) for new investigational medicinal products (originator drugs) addressing unmet cancer needs. Lead institute must be a Dutch medical centre or research institute. Patient involvement is mandatory. Repurposing of registered drugs and purely preclinical research are out of scope. Proposals must be submitted in English via KWF GMS.

Feasibility studies for commercial application of innovative knowledge from Dutch universities, UMCs, KNAW/NWO institutes, Netherlands Cancer Institute, Max Planck Institute Nijmegen, NCB Naturalis, ARCNL, or Princess Máxima Center. Applicants must be researchers at these institutions. Covers product, process, care, or service innovation across all scientific fields.

Open to researchers at Dutch universities, university medical centers, KNAW/NWO institutes, Netherlands Cancer Institute, Max Planck Institute for Psycholinguistics (Nijmegen), NCB Naturalis, ARCNL, and Princess Máxima Center. Funds feasibility studies for commercial application of innovative knowledge. Submitted via ISAAC. All scientific fields eligible.

Open to researchers with a tenured or tenure-track position at Dutch universities, UMCs, KNAW/NWO institutes, Netherlands Cancer Institute, Max Planck Institute Nijmegen, Naturalis, ARCNL, or Princess Máxima Center. Co-funding required (min. 25%) if total project costs exceed €700k. Not intended for clinical trials, contract research, or investment-dominated proposals. User committee of ≥4 knowledge users required.

Supports the transition of distinguished postdoctoral researchers into independent tenure-track investigators in cancer immunotherapy. Aimed at researchers at the postdoc-to-faculty transition stage.

For mid-career scientists (tenure-track assistant professors with ≥3 years or associate professors with ≤3 years in role) with MD, PhD, or MD/PhD. Minimum 80% time commitment to research. Open globally; host institution must be a non-profit medical school or research center (US or abroad). For-profit institutions ineligible. Adjunct/acting positions not eligible. Funds high-risk, high-reward cancer immunotherapy research.

Supports mid-career scientists pursuing high-risk, high-reward research at the leading edge of cancer immunotherapy. Targets established investigators with bold, transformative research directions.

Main grant round (Hoveduddeling) for project support in biological, clinical and translational cancer research. Proposals likely in Danish.

Main grant round (Hoveduddeling) for project support in humanities, social science, public health and epidemiological cancer research. Proposals likely in Danish.

Thematic cancer research grants funded through the Knæk Cancer fundraising campaign. Proposals likely in Danish. Full eligibility and thematic priorities available on the funder's website.

Grants for young talented cancer researchers (unge talentfulde kræftforskere), scholar stipends and international stays. Early-career focused. Proposals likely in Danish.

(Project support for establishing research careers) Open to independent cancer researchers who obtained their PhD within the last 8 years and have demonstrated high international research capacity. Applicants must already have secured funding for their own salary; 50% exemption from clinical work may be applied for. All aspects of cancer research are eligible.

(Postdoc fellowship in Denmark and abroad) For researchers with a PhD (max 4 years ago) without permanent employment, conducting an independent cancer research project in Denmark or abroad. The abroad variant targets Danish researchers going abroad independently — not employed by a Danish hospital, university, or company during the stay.

Supports early-career researchers who have never previously received AIRC funding, enabling independent project leadership at an Italian research institution. Covers research costs, the grant holder's salary, and two dedicated personnel. Projects selected by international peer review for cancer relevance, innovation, and feasibility. Host institution must be in Italy.

Two-year support for postdoctoral physicians and life scientists conducting projects in clinically-oriented oncological basic research or clinical cancer research at renowned institutions abroad or within Germany. (Postdoctoral Programme)

Open to researchers at non-profit research organisations based in Spain or Portugal. Thematic areas: neurosciences, oncology, cardiovascular and metabolic diseases, infectious diseases, and enabling technologies. Individual projects up to €500k; consortium projects (2–5 organisations) up to €1M. Submissions via the dedicated online platform only.

Fully funded 4-year PhD studentship (stipend + research costs) for students who self-identify as Black heritage (including mixed Black backgrounds). Open to non-clinical PhD candidates only. Fees covered at UK/home rate; international fee shortfall must be met by the host institution. Hosted at CRUK centres; applicants must meet standard PhD entry requirements including English language requirements set by the host institution.

Supports high-impact translational cancer research through the Transcan-4 European network. FWO funds the Belgian component of transnational consortia. Applicants must be affiliated with a Flemish research institution.

Supports biological, translational and clinical cancer research (Danish: biological cancer research, translational studies, clinical research). Open to cancer researchers at Danish institutions (universities, hospitals) and Danish researchers working abroad who will return results to Denmark. Covers salary, scientific/technical assistance, minor equipment and running costs. Proposals evaluated by KBVU-BK scientific committee.

5-year start-up grants for researchers of any nationality wishing to establish an independent cancer research laboratory in Italy after significant international experience. Covers research costs, salaries of two dedicated staff, and the PI's own salary. Selection via competitive international peer review; demonstrated leadership potential required. Host institution must be in Italy.

Grants for independent researchers establishing their own laboratory and conducting cancer research at an institution in southern or insular Italy (Mezzogiorno). Promotes collaboration networks with research groups elsewhere in Italy or abroad. Host institution must be located in southern/insular Italy. Page shows active grantees; no open application window currently visible.

Funds non-commercial, investigator-initiated cancer therapy trials (Investigator Initiated Trials). Applicants submit a short-form Part I application; Part II is submitted only upon invitation from Deutsche Krebshilfe. Requires patient recruitment plan and sponsor declaration. Proposals must be submitted in German.

Individual projects submitted by a single non-profit research organisation based in Spain or Portugal. Thematic areas: neurosciences, oncology, cardiovascular and associated metabolic diseases, infectious diseases, and enabling technologies in those areas. Applications must be submitted via the official online platform; other channels not accepted.

Summer laboratory internship grant in cancer research, 2026 call. Hosted at Spanish institutions. Aimed at students seeking early exposure to cancer research.

Accelerates conversion of promising scientific discoveries into cancer therapeutics. Translational/drug discovery focus. Open to investigators at academic institutions globally. No explicit eligibility restrictions stated.

Funds Nordic collaboration in cancer research to support and encourage cross-Nordic partnerships. Application period closes early September 2026. Requires collaboration between Nordic countries.

Supports humanistic, social, public health, and epidemiological cancer research at Danish institutions (universities, hospitals, etc.), or Danish researchers working abroad with results to be returned to Denmark. Covers researcher salary, scientific/technical assistance, minor equipment, and operating costs. Proposals reviewed by the KBVU-MS scientific committee. (Psychosocial & Epidemiological Cancer Research)

For clinician scientists seeking protected research time. Applicants must be clinicians with NHS programmed activities; host institution must support lab/office space for the award duration. Covers salary (up to 11 PAs), £6.5k annual supplement, up to 2 staff posts (technician, postdoc, and/or non-clinical PhD student), and running expenses. Cancer research focus required.

Open to academic researchers worldwide (university or research institute) with independent lab. Funds early drug discovery for childhood and young people's cancers: target deconvolution/validation, novel therapeutic approaches, target identification, and de-risking. Projects run collaboratively with Cancer Research Horizons' Therapeutic Innovation team. Excludes basic biology, clinical development, and drug repurposing.

For clinicians in specialty/run-through training eligible to practise medicine in the UK, hosted at a UK university, hospital, or UKCRC-registered CTU. Requires 50% matched funding from host institution. Applicant must collaborate with a UKCRC-registered CTU. Covers 50% of salary and 50% of running expenses. Cancer-relevant clinical trials training; must gain experience across multiple trials.

Supports high-risk, high-reward cancer research worldwide across basic research, therapeutic discovery, innovative technologies, and early-stage clinical trials. PIs must be independent researchers. Applications are by invitation or via RFPs; unsolicited applications are not accepted. Indirect costs capped at 10% of direct costs. Revenue sharing terms apply.

Biomedical and health research (basic, clinical, translational) in neuroscience, oncology, cardiovascular/metabolic disease, infectious diseases, and enabling technologies. Host Organization must be a non-profit research institution based in Spain or Portugal. Applications must be submitted in English. Budget of non-Spanish/Portuguese partners may not exceed 30% of total project budget.

Sachbeihilfen (project grants) for innovative research in cancer prevention and early detection (Krebs-Prävention und -Früherkennung). Includes validation and establishment of new early-detection methods (e.g. biomarkers, imaging). Applicants should follow the guidelines from the 'Versorgungsmaßnahmen und -forschung' programme. Proposals must be submitted in German.